Phoenix 8.1

Phoenix 8.1 DEV

Phoenix PK/PD Modeling and Simulation Software Certara’s Phoenix platform is the leading PK/PD modeling and simulation software used worldwide by 6,000 researchers at biopharmaceutical companies, academic institutions, and global regulatory agencies, including eleven divisions of the US FDA. Phoenix extends the winning formula of WinNonlin by combining its trusted algorithms with built-in, easy-to-use graphical user […]

Read More
Topics:

Phoenix 8.1

Phoenix PK/PD Modeling and Simulation Software Certara’s Phoenix platform is the leading PK/PD modeling and simulation software used worldwide by 6,000 researchers at biopharmaceutical companies, academic institutions, and global regulatory agencies, including eleven divisions of the US FDA. Phoenix extends the winning formula of WinNonlin by combining its trusted algorithms with built-in, easy-to-use graphical user […]

Read More
Topics:

Training Your Way

E-learning Courses: Training at Your Convenience Certara University has expanded its educational reach via the introduction of an e-learning platform. E-learning classes are now available in various topics such as Introduction to Phoenix Winnonlin, Population Modeling Using Phoenix NLME, Fundamentals of Pharmacokinetics, Non-compartmental Data Analysis, Introduction to Statistics with R, and many other courses. See […]

Read More
Topics:

Burstable Compute Grid

Power Up Your Models with a Cloud-based Compute Grid Computationally-intensive PK/PD modeling and simulation applications, such as Phoenix® NLME™ and NONMEM®, require significant compute power to process models. Depending on the size and complexity of the job, models run on a local dual- or quad-core computer using serial computation can take 8 hours to days […]

Read More
Topics:

Trainers

Meet the Certara University Trainers Nathan Teuscher is a leader in the pharmaceutical industry as a scientist, consultant, and teacher. Nathan has been teaching and training for over 15 years in the pharmaceutical industry, providing lectures in general pharmacokinetics to non-scientists, and specialized training in population pharmacokinetics and drug development to industry experts. Nathan also […]

Read More
Topics:

Training Your Way

Classroom Courses: Training in Group Settings Certara’s classroom trainings are offered by our scientific experts and leadership in variety of topics including: Population Modeling Methodology IVIVC Toolkit for Phoenix WinNonlin—In Vivo-In Vitro Correlations Intermediate PK/PD Modeling Methodology Variety of Simcyp Workshops Classroom trainings are offered around the globe and course schedules are posted on the Certara […]

Read More
Topics:

On-site Training

On-site Training: We’ll Come to You Certara University trainers deliver PK/PD modeling and simulation courses at your site! Certara’s on-site training is one of the most cost-effective ways to facilitate your organization’s learning and development goals. Choose from our standard curriculum or customize training to fit your organization’s needs with an expert on-site. We will […]

Read More
Topics:

The Phoenix Reporter

A Compendium of Insightful Information for Our Phoenix Community, Vol. 3 Welcome to The Phoenix® Reporter. In this e-newsletter, we will share informative educational content along with practical, implementable resources with our Phoenix user community. This issue provides an overview of the new features and enhancements in Phoenix 8.0, the newest version of our PK/PD software: Phoenix WinNonlin 8.0—Taking […]

Read More
Topics:

.AD — Choosing the Right Software for PK/PD Analysis

Choosing the Right Software for PK/PD Analysis The methods used to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of a compound can be inherently complex and sophisticated. PK/PD analysis is a science that requires a mathematical and statistical background, combined with an understanding of biology, pharmacology, and physiology. PK/PD analysis guides critical decisions in drug […]

Read More
Topics:

Clinical Outcomes Databases for Specific Therapeutic Areas

About our Clinical Trial Outcomes Databases Our Clinical Trial Outcomes Databases form a quantitative framework to leverage valuable external data, providing key development insights to maximize the probability of success for a new drug. Comparative effectiveness Endpoint and subpopulation relationships Biomarker efficacy and safety outcome Trial design optimization Competitive analysis and commercial viability Gathering, formatting, […]

Read More
Topics:

Immunology

Strategic Modeling and Simulation Services for Autoimmune Disorders Certara Strategic Consulting scientists have extensive experience in immunological disorders. We have also leveraged comparator data to support Phase 2b dose selection for the treatment of autoimmune disorders. Disease Areas Rheumatoid arthritis Psoriasis Crohn’s disease Systemic sclerosis Multiple sclerosis Clinical Trial Outcomes Databases We have developed an […]

Read More
Topics:

Certara University

The Importance of Modeling & Simulation Education Certara University is dedicated to shaping the future of healthcare innovation through modeling and simulation education. Certara University provides modeling and simulation education, skills, and expertise in the global healthcare industry. We recognize that continuing education in both the theory and practice of modeling and simulation in drug […]

Read More
Topics:

Oncology

Oncology: Strategic Modeling and Simulation Services Certara has extensive experience supporting oncology drug development. In addition, we have applied a range of modeling techniques to address critical decisions from pre-clinical to late stage clinical for antibodies, proteins and small molecules, such as C-QT modeling, metadata analysis, preclinical to Phase 2 PK and TK analysis, and […]

Read More
Topics:

Infectious Disease

Infectious Disease: Strategic Modeling and Simulation Services Drug development for infectious diseases faces unique challenges including compliance, viral dynamics, and drug resistance. Certara has extensive experience in infectious disease projects, including many HIV and HCV viral dynamics/kinetics modeling projects over the past decade, in all clinical development phases. We have covered critical issues in trial […]

Read More
Topics:

Endocrinology

Endocrinology: Strategic Modeling and Simulation Services Certara has broad expertise in endocrine diseases including diabetes, obesity, hypogonadism, and hypoparathyroidism. For example, our scientists have supported diabetes development programs for industry clients, from pre-clinical to Phase 4 commercial strategy. Our consultants have addressed critical issues in trial design, dose selection, extrapolation from animal to human, and development […]

Read More
Topics:

Central Nervous System

Central Nervous System: Strategic Modeling and Simulation Services Certara has extensive experience supporting Central Nervous System (CNS) projects for industry clients, spanning all phases of clinical development. Our consultants have addressed key issues in trial design, choice of indication, and development strategy for drugs with novel mechanisms of action. We have developed models for assessing […]

Read More
Topics:

Cardiovascular

Cardiovascular: Strategic Modeling and Simulation Services Certara has extensive experience in modeling and simulation to support cardiovascular drug development across all phases of clinical development. Our consultants have addressed key issues in trial design, dose selection, and development strategy for a broad range of cardiovascular diseases and conditions, including pulmonary arterial hypertension (PAH), congestive heart […]

Read More
Topics:

Therapeutic Areas

Therapeutic Areas of Expertise: Strategic Drug Development Services Certara’s global consulting team has unparalleled experience across all development phases and in all major therapeutic areas. We have collaborated with sponsors, both large and small to provide insight into key decisions, including dosing and toxicity; efficacy and biological impact; comparative effectiveness; clinical trial design; regulatory strategy; and […]

Read More
Topics:
Learn More LinkedIn Twitter Facebook Email Subscribe to the Blog